Stockscreener 앱 받기
1.28
0.78%
-0.01
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit - BioSpace
Price to book forward of Lineage Cell Therapeutics, Inc. – AMEX:LCTX - TradingView
Price to sales forward of Lineage Cell Therapeutics, Inc. – AMEX:LCTX - TradingView
LCTX Q1 2026 Earnings: EPS Misses Estimates Despite Positive Stock ReactionShare Dilution Risk - dars.gov.et
LCTXLineage Cell Therapeutics Inc Stock Price and Quote - Finviz
Form 4 Lineage Cell Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Lineage Cell (LCTX) director granted 125,000 options at $1.30 strike - Stock Titan
Lineage Cell Therapeutics (LCTX) director receives 125,000 stock options at $1.30 - Stock Titan
Lineage Cell Therapeutics (LCTX) director awarded 125,000 stock options at $1.30 - Stock Titan
Lineage Cell Therapeutics (LCTX) director granted 125,000 options at $1.30 strike - Stock Titan
Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call - Benzinga
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Lineage Cell Therapeutics, Inc.(NYSEAM: LCTX) added to Russell 2000 Index - marketscreener.com
Lineage Cell Therapeutics, Inc.(NYSEAM: LCTX) added to Russell 2500 Growth Benchmark - marketscreener.com
Lineage Cell Therapeutics, Inc.(NYSEAM: LCTX) added to Russell 2000 Growth Benchmark - marketscreener.com
Lineage Cell Therapeutics, Inc.(NYSEAM: LCTX) added to Russell 3000E Index - marketscreener.com
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of Lineage Cell Therapeutics, Inc. – LSX:A2PP89 - TradingView
BT3 Forecast — Price Target — Prediction for 2027 - TradingView
Lineage Cell Therapeutics, Inc. Actuals & Estimates (TASE:LCTX) - TradingView
LCTX Holds Tight Range As Traders Eye Next Break - StocksToTrade
LCTX Edges Higher As Traders Focus On Tight Range Break - timothysykes.com
LCTX Edges Higher As Traders Focus On Tight Range Setup - StocksToTrade
LCTX Forecast — Price Target — Prediction for 2027 - TradingView
Lineage Cell Therapeutics, Inc. Actuals & Estimates (DUS:BT3) - TradingView
Lineage Cell Therapeutics Inc. (LCTX) Q1 2026 Earnings: EPS Miss Weighs on Pre-Revenue Biotech - dars.gov.et
Streamlined procurement and lean AP workflows drive efficiency at Lineage Cell Therapeutics - Traders Union
Enterprise value to EBITDA forward of Lineage Cell Therapeutics, Inc. – AMEX:LCTX - TradingView
Enterprise value to EBITDA forward of Lineage Cell Therapeutics, Inc. – LSX:A2PP89 - TradingView
Aardvark Therapeutics Leads The Charge With 2 Other Noteworthy Penny Stocks - simplywall.st
Lineage Cell Therapeutics Inc (LCTX) Institutional Confidence - TradingKey
LCTX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineEarnings Expansion Phase - dars.gov.et
Lineage Cell Therapeutics Inc (LCTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lineage Cell Therapeutics (LCTX) Stock Faces Mixed Analyst Target Changes After Fresh Coverage - Yahoo Finance
Lineage Cell Therapeutics Inc (LCTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lineage Cell Therapeutics Inc - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lineage Cell Therapeutics joins panel on novel treatments at Clinical Trials at the Summit - Traders Union
Lineage Cell Shareholders Reaffirm Governance and Executive Pay - The Globe and Mail
Lineage Cell (NYSE: LCTX) investors back board, say-on-pay as OPC1 grant bid withdrawn - Stock Titan
LCTX Q1 2026 Earnings: EPS Miss Reflects Ongoing R&D InvestmentTrough Earnings Signal - newsline.com
LCTX Q1 2026 Earnings: EPS Misses Estimates by 47% as Company Continues Clinical DevelopmentReturn On Assets - newsline.com
How The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst Targets - Yahoo Finance
LCTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lineage Cell Therapeutics (LCTX) price target increased by 14.58% to 5.61 - MSN
LCTX Q1 2026 Earnings: Wider Loss Than Expected Amid Ongoing Pipeline DevelopmentForward EPS Estimate - newsline.com
LCTX Q1 2026 Earnings: Missed Estimates as R&D Spending Weighs on Bottom LineHealthcare Earnings Report - The Legal Advocate
Lineage Cell Therapeutics (LCTX) Gains 3% as Biotech Sector Finds SupportNHNL Ratio - The Legal Advocate
Lineage Cell Therapeutics Inc. (LCTX) Q1 2026 Earnings: EPS Misses Estimates Amid Pipeline Progress, Stock Rises 3.08%Annual Earnings Summary - The Legal Advocate
Lineage Cell Therapeutics spotlights CEO participation in fireside chat with HCWCO at BioConnect - Traders Union
2.64%
자본화:
|
볼륨(24시간):